The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition

Keyphrases

• Adenylyl Cyclase 100%
• Channel Activation 100%
• D2 Dopamine Receptor 100%
• D2 Receptor 100%
• D2-like 66%
• D3 Dopamine Receptor 33%
• D4 Dopamine Receptor 33%
• Dopamine Receptor 100%
• Dopaminergic Pathway 33%
• Electrophysiological Assays 33%
• Forskolin 33%
• G Protein-coupled Inwardly Rectifying Potassium Channels 33%
• GIRK Channel 100%
• High Affinity 33%
• Indol 33%
• Inhibition Assay 33%
• Intrinsic Efficacy 33%
• Methoxy 33%
• Methyl 33%
• Methylthiol 33%
• Movement Disorders 33%
• Neurological Disorders 33%
• Neuropsychiatric Disorders 33%
• Neutral Antagonist 33%
• Pharmacological Tools 33%
• Phenyl 33%
• Piperidin-4-ol 33%
• Quinpirole 33%
• Receptor Agonist 33%
• Receptor-mediated 100%
• Selective Antagonist 100%

Neuroscience

• Adenylyl Cyclase 100%
• D2-Like Receptor 33%
• Dopamine Receptor 33%
• Dopamine Receptor D2 100%
• Dopaminergic 33%
• Forskolin 33%
• G Protein-Coupled Inwardly-Rectifying Potassium Channel 100%
• In Vitro 33%
• In Vivo 33%
• Neurological Disorder 33%
• Quinpirole 33%
• Receptor 100%
• Receptor Agonists 33%
• Receptor Subtype 100%
• Stereotypic Movement Disorder 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenylate Cyclase 100%
• Dopamine Receptor 33%
• Dopamine Receptor D2 100%
• Dopamine Receptor Stimulating Agent 33%
• Forskolin 33%
• G Protein Coupled Inwardly Rectifying Potassium Channel 100%
• Indole 33%
• Motor Dysfunction 33%
• Neurologic Disease 33%
• Quinpirole 33%
• Receptor 100%
• Receptor Agonist 33%
• Receptor Subtype 100%